Author: Zhang, Yueyang ; Wang, Weidong ; Jin, Yanxia ; Sun, Hui ; Wang, Xiaoyu ; Zhu, Haibo ; Chen, Ying ; Gong, Yongsheng ; Tian, Leyi ; Wu, Aobo ; Pan, Jicheng

Selenium nanoparticles (SeNPs) have limited bioavailability because of their poor stability in aqueous solutions. AAGL, a naturally active protein, extracted from Agrocybe aegerita has strong antitumor activity. However, whether AAGL can been used to stabilize SeNPs, and exerts anti-lung cancer effects remains unknown. In this study, a novel nanocomposite, AAGL-SeNPs, was prepared using AAGL-encapsulated SeNPs. The particle size of the AAGL-SeNPs was approximately 206.1 nm, which was uniform and well dispersed in aqueous solution and showed satisfactory stability. AAGL-SeNPs was non-toxic and reduced the hepatotoxicity of AAGL in mice. Importantly, AAGL-SeNPs inhibited the proliferation of lung cancer cells and suppressed tumor growth in tumor-bearing mice. AAGL-SeNPs enhanced the cytotoxic effects on lung cancer cells by stimulating immune cells. In addition, the combination of AAGL-SeNPs and osimertinib inhibited lung cancer, and AAGL-SeNPs reversed osimertinib resistance in H1975 cells. Mechanistically, Krüppel-like transcriptional factor 4 (KLF4) was identified by data-independent acquisition mass spectrometry (DIA-MS), and its expression levels in lung cancer increased after AAGL-SeNPs treatment. This study demonstrated that nanocomposite AAGL-SeNPs is stable, safe, and has excellent antitumor efficacy, which will be a potential therapeutic drug for lung cancer treatment.

01 Dec 2024·Journal of Trace Elements in Medicine and Biology

The integrated effect of roflumilast and selenium nanoparticles on nephrotoxicity generated by cisplatin through the regulation of the antioxidant and apoptotic pathways

Article

Author: Barakat, Nashwa ; Zahran, Faten ; Ismail, Ehab

AIMThe current investigations aimed to investigate the potential synergistic effect of Roflumilast (ROF) and Selenium nanoparticles (SeNPs) administration on Cisplatin (Cis) -induced nephrotoxicity.MATERIALS AND METHODSFifty male rats were divided into five groups; Control group: animals were administered 0.9 % saline solution. Cis group: animals were injected with a single dose of 6 mg/kg. ROF group: Rats received a dosage of 1.2 mg/kg orally daily for 11 days. SeNPs group: animals orally received 0.5 mg/kg of ROF daily for 11 days. The ROF + SeNPs group was administered both after receiving a Cis injection for 11 days. Animals were sacrificed at 5 and 11 days, and the urine and blood samples were collected on day 5 and day 11 for chemical analysis, while kidney samples were obtained for molecular, histological, and immunohistochemical studies.RESULTSThe levels of serum creatinine, Blood urea nitrogen (BUN), and total protein were elevated in the Cis group compared to the control group (p < 0.05). While the combination of ROF and SeNPs dramatically decreased these values after 5 and 11 days (p < 0.05). In addition, Cis caused renal oxidative stress by elevating MDA levels and suppressing the activities of SOD, GSH, and CAT. Similarly, these effects were modulated by ROF and SeNPs after 11 days (p < 0.05). Furthermore, the concurrent administration of ROF and SeNPs resulted in a significant increase in the expression of HO-1, Nrf2, and Bcl2, while decreasing the expression of BAX and IL-6 compared to the Cis group after 11 days (P < 0.05).CONCLUSIONThe study showed that both ROF and SeNPs had significant therapeutic potential in reducing the pathological alterations caused by Cis.

01 Dec 2024·International Journal of Biological Macromolecules

Innovative anticancer nanocomposites from Corchorus olitorius mucilage/chitosan/selenium nanoparticles

Article

Author: El-Sherbiny, Mohsen M. ; El-Sherbiny, Mohsen M ; Tayel, Ahmed A ; El-Hefnawy, Mohamed E ; El-Hefnawy, Mohamed E. ; Tayel, Ahmed A.

Cancers are continuing to threaten human health globally; the achievement of effectual and biosafe anticancerous compounds is a precious goal. The extraction of Corchorus olitorius mucilage (Jm) and its usage for selenium nanoparticles (SeNPs) biosynthesis was projected. The innovative formulation of bioactive nanocomposites (NCs) from Jm/SeNPs and chitosan nanoparticles (Cht) was also proposed to apply these NCs as effectual anticancers against CaCo-2 and HeLa cancerous cells. The Jm/SeNPs biosynthesis (mean diameter = 6.45 nm) was innovatively achieved and confirmed using infrared and ultraviolet-visible analysis. The constructions of different NCs were done (N1: 2Jm/SeNPs:1Cht; N2: 1Jm/SeNPs:1Cht; and N3: 1Jm/SeNPs:2Cht) with mean particles' diameter of 88.41, 46.86 and 69.35 nm, respectively. The cytotoxicity assay of constructed NCs indicated their potentialities to suppress examined cells; N1 (negatively charged; -16.2 mV) was the most forceful with IC₅₀ of 12.36 and 73.15 mg/L against CaCo-2 and HeLa cells, respectively. The scanning microscopy imaging of treated CaCo-2 cells with N1 of Cht/Jm/SeNPs indicated that the NCs led to remarkable apoptotic destructions of treated cells, including cell shrinkage, membrane blebbing, cytoplasmic vacuolization, cell debris and apoptotic indices. The innovative NCs from Cht/Jm/SeNPs are promisingly recommended as effectual, natural and bioactive anticancer formulations against human cancers.

100 Deals associated with Selenium nanoparticles(SeNPs)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ischemic nephropathy	Preclinical	CN	Affiliated Hospital of Guangdong Medical University	25 Jul 2024
Reperfusion Injury	Preclinical	CN	Affiliated Hospital of Guangdong Medical University	25 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Selenium nanoparticles(SeNPs)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation